Biliang Hu

Jan 8, 2025 | nature.com | Georg Schett |Biliang Hu

Dear Editor, Rheumatoid arthritis (RA) is an autoimmune inflammatory disease characterized by symmetric synovial inflammation leading to progressive disability.1 Treatment of RA has been revolutionized by the development of monoclonal antibodies against cytokines (e.g., tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6)) as well as B-cells (e.g., CD20-targeted antibody rituximab), resulting in better disease control.2 However, up to 30% of RA patients still escape therapeutic responses...